TNP-2092 capsules

DRUG4 trials

Sponsors

TenNor Therapeutics (Suzhou) Limited, TenNor Therapeutics Inc.

Conditions

Helicobacter Pylori InfectionHyperammonemia

Phase 1

PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

CompletedNCT06135675

TenNor Therapeutics (Suzhou) LimitedHyperammonemia

Start: 2020-08-27End: 2021-06-16Updated: 2025-04-25

A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 Capsules

CompletedNCT06178718

TenNor Therapeutics (Suzhou) LimitedHyperammonemia

Start: 2016-06-06End: 2016-08-02Updated: 2025-04-25

A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects

CompletedNCT06190340

TenNor Therapeutics (Suzhou) LimitedHelicobacter Pylori Infection

Start: 2016-11-08End: 2017-09-26Updated: 2025-02-27

The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets

CompletedNCT06337604

TenNor Therapeutics Inc.Helicobacter Pylori Infection

Start: 2017-10-10End: 2017-11-23Updated: 2024-04-01